96 related articles for article (PubMed ID: 11159510)
21. In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.
Karami S; Roshandel E; Ghaffari Nazari H; Hajifathali A; Tavakoli F; Parkhideh S
Virusdisease; 2021 Sep; 32(3):422-434. PubMed ID: 34631973
[TBL] [Abstract][Full Text] [Related]
22. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
23. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.
Fuji S; Byrne M; Nagler A; Mohty M; Savani BN
Bone Marrow Transplant; 2021 Jun; 56(6):1248-1256. PubMed ID: 33514922
[TBL] [Abstract][Full Text] [Related]
24. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation.
Duke ER; Williamson BD; Borate B; Golob JL; Wychera C; Stevens-Ayers T; Huang ML; Cossrow N; Wan H; Mast TC; Marks MA; Flowers ME; Jerome KR; Corey L; Gilbert PB; Schiffer JT; Boeckh M
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32970635
[TBL] [Abstract][Full Text] [Related]
25. Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
Shafat MS; Mehra V; Peggs KS; Roddie C
Front Immunol; 2020; 11():1694. PubMed ID: 32849591
[TBL] [Abstract][Full Text] [Related]
26. CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation.
Kaeuferle T; Deisenberger L; Jablonowski L; Stief TA; Blaeschke F; Willier S; Feuchtinger T
Mol Ther; 2020 Sep; 28(9):1965-1973. PubMed ID: 32559432
[TBL] [Abstract][Full Text] [Related]
27. Unusual cause for intestinal perforation in juvenile dermatomyositis.
Bhaskaran H; Balan S
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31444261
[TBL] [Abstract][Full Text] [Related]
28. The gut microbiota and graft-versus-host disease.
Fredricks DN
J Clin Invest; 2019 May; 129(5):1808-1817. PubMed ID: 31042160
[TBL] [Abstract][Full Text] [Related]
29. Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.
Metafuni E; Chiusolo P; Sica S; Laurenti L; Bregante S; Van Lint MT; Dominietto A; Angelucci E; Bacigalupo A
Bone Marrow Transplant; 2018 Dec; 53(12):1560-1567. PubMed ID: 29795416
[TBL] [Abstract][Full Text] [Related]
30. Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation.
Styczynski J
Infect Dis Ther; 2018 Mar; 7(1):1-16. PubMed ID: 29204910
[TBL] [Abstract][Full Text] [Related]
31. Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation.
Golob JL; Pergam SA; Srinivasan S; Fiedler TL; Liu C; Garcia K; Mielcarek M; Ko D; Aker S; Marquis S; Loeffelholz T; Plantinga A; Wu MC; Celustka K; Morrison A; Woodfield M; Fredricks DN
Clin Infect Dis; 2017 Nov; 65(12):1984-1991. PubMed ID: 29020185
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for transplantation-associated viral infections.
Roddie C; Peggs KS
J Clin Invest; 2017 Jun; 127(7):2513-2522. PubMed ID: 28628043
[TBL] [Abstract][Full Text] [Related]
33. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.
Rose J; Emery VC; Kumar D; Asberg A; Hartmann A; Jardine AG; Bignamini AA; Humar A; Neumann AU
PLoS Pathog; 2017 Apr; 13(4):e1006299. PubMed ID: 28406982
[TBL] [Abstract][Full Text] [Related]
34. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.
El Chaer F; Shah DP; Chemaly RF
Blood; 2016 Dec; 128(23):2624-2636. PubMed ID: 27760756
[TBL] [Abstract][Full Text] [Related]
35. Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China.
Bao X; Zhu Q; Xue S; Xu Y; Ma X; Chen F; Hu X; Zhu Z; Chen S; Sun A; Wu D; Song Y; Qiu H
Bone Marrow Transplant; 2016 Dec; 51(12):1625-1627. PubMed ID: 27748738
[No Abstract] [Full Text] [Related]
36. Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.
Griffiths PD; Rothwell E; Raza M; Wilmore S; Doyle T; Harber M; O'Beirne J; Mackinnon S; Jones G; Thorburn D; Mattes F; Nebbia G; Atabani S; Smith C; Stanton A; Emery VC
PLoS One; 2016; 11(9):e0163722. PubMed ID: 27684379
[TBL] [Abstract][Full Text] [Related]
37. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
38. Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.
Keller MD; Bollard CM
Immunotargets Ther; 2014; 3():97-106. PubMed ID: 27274983
[TBL] [Abstract][Full Text] [Related]
39. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
Rustia E; Violago L; Jin Z; Foca MD; Kahn JM; Arnold S; Sosna J; Bhatia M; Kung AL; George D; Garvin JH; Satwani P
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1646-1653. PubMed ID: 27252110
[TBL] [Abstract][Full Text] [Related]
40. Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.
Barger-Kamate B; Forman M; Sangare CO; Haidara AS; Maiga H; Vaidya D; Djimde A; Arav-Boger R
J Clin Virol; 2016 Apr; 77():40-5. PubMed ID: 26895228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
